Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376149738> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4376149738 abstract "<div>AbstractPurpose:<p>High levels of type I T cells are needed for tumor eradication. We evaluated whether the HER2-specific vaccine–primed T cells are readily expanded <i>ex vivo</i> to achieve levels needed for therapeutic infusion.</p>Patients and Methods:<p>Phase I/II nonrandomized trial of escalating doses of <i>ex vivo</i>–expanded HER2-specific T cells after <i>in vivo</i> priming with a multiple peptide–based HER2 intracellular domain (ICD) vaccine. Vaccines were given weekly for a total of three immunizations. Two weeks after the third vaccine, patients underwent leukapheresis for T-cell expansion, then received three escalating cell doses over 7- to 10-day intervals. Booster vaccines were administered after the T-cell infusions. The primary objective was safety. The secondary objectives included extent and persistence of HER2-specific T cells, development of epitope spreading, and clinical response. Patients received a CT scan prior to enrollment and 1 month after the last T-cell infusion.</p>Results:<p>Nineteen patients received T-cell infusions. Treatment was well tolerated. One month after the last T-cell infusion, 82% of patients had significantly augmented T cells to at least one of the immunizing epitopes and 81% of patients demonstrated enhanced intramolecular epitope spreading compared with baseline (<i>P</i> < 0.05). There were no complete responses, one partial response (6%), and eight patients with stable disease (47%), for a disease control rate of 53%. The median survival for those with progressive disease was 20.5 months and for responders (PR+SD) was 45.0 months.</p>Conclusions:<p>Adoptive transfer of HER2 vaccine–primed T cells was feasible, was associated with minimal toxicity, and resulted in an increased overall survival in responding patients.</p></div>" @default.
- W4376149738 created "2023-05-12" @default.
- W4376149738 creator A5021384712 @default.
- W4376149738 creator A5027006941 @default.
- W4376149738 creator A5033152420 @default.
- W4376149738 creator A5043685783 @default.
- W4376149738 creator A5053687578 @default.
- W4376149738 creator A5060994391 @default.
- W4376149738 creator A5065386585 @default.
- W4376149738 creator A5085036384 @default.
- W4376149738 creator A5050196869 @default.
- W4376149738 date "2023-05-11" @default.
- W4376149738 modified "2023-09-27" @default.
- W4376149738 title "Data from A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer" @default.
- W4376149738 doi "https://doi.org/10.1158/1078-0432.c.6641713.v1" @default.
- W4376149738 hasPublicationYear "2023" @default.
- W4376149738 type Work @default.
- W4376149738 citedByCount "0" @default.
- W4376149738 crossrefType "posted-content" @default.
- W4376149738 hasAuthorship W4376149738A5021384712 @default.
- W4376149738 hasAuthorship W4376149738A5027006941 @default.
- W4376149738 hasAuthorship W4376149738A5033152420 @default.
- W4376149738 hasAuthorship W4376149738A5043685783 @default.
- W4376149738 hasAuthorship W4376149738A5050196869 @default.
- W4376149738 hasAuthorship W4376149738A5053687578 @default.
- W4376149738 hasAuthorship W4376149738A5060994391 @default.
- W4376149738 hasAuthorship W4376149738A5065386585 @default.
- W4376149738 hasAuthorship W4376149738A5085036384 @default.
- W4376149738 hasConcept C100701293 @default.
- W4376149738 hasConcept C126322002 @default.
- W4376149738 hasConcept C150903083 @default.
- W4376149738 hasConcept C159654299 @default.
- W4376149738 hasConcept C195616568 @default.
- W4376149738 hasConcept C203014093 @default.
- W4376149738 hasConcept C207001950 @default.
- W4376149738 hasConcept C26291073 @default.
- W4376149738 hasConcept C2776090121 @default.
- W4376149738 hasConcept C2776789287 @default.
- W4376149738 hasConcept C59822182 @default.
- W4376149738 hasConcept C71924100 @default.
- W4376149738 hasConcept C81444415 @default.
- W4376149738 hasConcept C86803240 @default.
- W4376149738 hasConcept C8891405 @default.
- W4376149738 hasConceptScore W4376149738C100701293 @default.
- W4376149738 hasConceptScore W4376149738C126322002 @default.
- W4376149738 hasConceptScore W4376149738C150903083 @default.
- W4376149738 hasConceptScore W4376149738C159654299 @default.
- W4376149738 hasConceptScore W4376149738C195616568 @default.
- W4376149738 hasConceptScore W4376149738C203014093 @default.
- W4376149738 hasConceptScore W4376149738C207001950 @default.
- W4376149738 hasConceptScore W4376149738C26291073 @default.
- W4376149738 hasConceptScore W4376149738C2776090121 @default.
- W4376149738 hasConceptScore W4376149738C2776789287 @default.
- W4376149738 hasConceptScore W4376149738C59822182 @default.
- W4376149738 hasConceptScore W4376149738C71924100 @default.
- W4376149738 hasConceptScore W4376149738C81444415 @default.
- W4376149738 hasConceptScore W4376149738C86803240 @default.
- W4376149738 hasConceptScore W4376149738C8891405 @default.
- W4376149738 hasLocation W43761497381 @default.
- W4376149738 hasOpenAccess W4376149738 @default.
- W4376149738 hasPrimaryLocation W43761497381 @default.
- W4376149738 hasRelatedWork W1486092468 @default.
- W4376149738 hasRelatedWork W1495379793 @default.
- W4376149738 hasRelatedWork W155248953 @default.
- W4376149738 hasRelatedWork W1986351546 @default.
- W4376149738 hasRelatedWork W2019087580 @default.
- W4376149738 hasRelatedWork W2020760178 @default.
- W4376149738 hasRelatedWork W2057384526 @default.
- W4376149738 hasRelatedWork W2142769285 @default.
- W4376149738 hasRelatedWork W2153088490 @default.
- W4376149738 hasRelatedWork W2414203182 @default.
- W4376149738 isParatext "false" @default.
- W4376149738 isRetracted "false" @default.
- W4376149738 workType "article" @default.